Skip to content

Clinical research of Gynecological YangXue granule on treating menostaxis after cesarean scar diverticulum

Clinical research of Gynecological YangXue granule on treating menostaxis after cesarean scar diverticulum

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-17011323
Enrollment
Unknown
Registered
2017-05-08
Start date
2017-05-25
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

????????????????

Interventions

experimental group:Begin on the third day of menstruation period (The first, second and third), Gynecological YangXue granule 1 packet, po bid, for two weeks.

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
24 Years to 45 Years

Inclusion criteria

Inclusion criteria: Conform to the Western Medicial diagnosis of scar diverticulum; Conform to menostaxis syndrom of qi and blood deficiency in TCM; 1. Women aged 24 to 45 year old; 2. Patients with a medical history over half a year of caesarean section,without intrauterine device; 3. Ultrasonic examination of gynecopathy demonstrates Cesarean Scar Diverticulum; 4. Patients with menostaxis or uterine bleeding syndrom,blood latency over eight days;with a normal period and course of disease over two months; 5. Patients belong to qi and blood deficiency in TCM syndrom; 6. Urine pregnancy test results negative;Agree with contraception during the research; 7. Voluntary trial and signed informed consent.

Exclusion criteria

Exclusion criteria: With any one of the circumstance below: 1. Blood latency two days(not include two days)before menstruation;Routine blood test shows hemoglobin below 90g/L; 2. Irregular colporrhagia caused by Endometrial Polyp,Endometrial Hyperplasia,submucosal leiomyoma of the uterus; 3. Patients with malignant tumor; 4. Patients complicated other severe diseasessuch as angiocarpy,liver,kidney,brain,lung and so on; 5. No drug effect on patients with high blood pressure and diabetes; 6. Patients with mental disease; 7. Be allergic to drug therapy; 8. Pregnant women or women of lactation; 9. Participate in another clinical trial now or one month ago; 10. Topical treatments with hormone within 3 months; 11. cervical cytology abnormity.

Design outcomes

Primary

MeasureTime frame
the lasting time of menstruation period;Gynecologic ultrasonography;

Secondary

MeasureTime frame
Routine blood test;Routine urine test;Stool-RT;Urine pregnancy test;

Countries

China

Contacts

Public ContactXuefang Liang

Guangdong Provincial Hospital of Chinese Medicine

liangxuefang2006@126.com+86 13926082916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026